{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BCG&page=2",
    "query": {
      "intervention": "BCG",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=BCG&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-09T14:49:13.455Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05825950",
      "title": "Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Non-muscle-invasive Bladder Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 600,
      "start_date": "2024-01-25",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2026-08-24",
      "last_synced_at": "2026-09-09T14:49:13.455Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas • San Antonio, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05825950"
    },
    {
      "nct_id": "NCT04564781",
      "title": "Predicting BCG Response",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "18 Years to 90 Years"
      },
      "enrollment_count": 400,
      "start_date": "2020-09-18",
      "completion_date": "2030-02",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-09-09T14:49:13.455Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • San Francisco, California • Dallas, Texas",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04564781"
    },
    {
      "nct_id": "NCT02449239",
      "title": "Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Vicinium",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sesen Bio, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 133,
      "start_date": "2015-08",
      "completion_date": "2022-05",
      "has_results": true,
      "last_update_posted_date": "2023-07-24",
      "last_synced_at": "2026-09-09T14:49:13.455Z",
      "location_count": 61,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 53 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02449239"
    },
    {
      "nct_id": "NCT01778569",
      "title": "The Psoriasis, Atherosclerosis, and Cardiometabolic Disease Initiative (PACI)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Metabolic Disease",
        "Cardiovascular Disease",
        "Inflammation",
        "Psoriasis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 386,
      "start_date": "2013-01-22",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-09-09T14:49:13.455Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01778569"
    },
    {
      "nct_id": "NCT00607230",
      "title": "Determination of Dosing and Frequency of BCG Administration to Alter T-Lymphocyte Profiles in Type I Diabetics",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Type 1 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "BCG",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 25,
      "start_date": "2007-11",
      "completion_date": "2011-02",
      "has_results": false,
      "last_update_posted_date": "2013-11-05",
      "last_synced_at": "2026-09-09T14:49:13.455Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00607230"
    },
    {
      "nct_id": "NCT03305341",
      "title": "Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "24 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "24 Years to 64 Years"
      },
      "enrollment_count": 20,
      "start_date": "2025-05-18",
      "completion_date": "2026-12-28",
      "has_results": false,
      "last_update_posted_date": "2026-06-10",
      "last_synced_at": "2026-09-09T14:49:13.455Z",
      "location_count": 1,
      "location_summary": "North Bethesda, Maryland",
      "locations": [
        {
          "city": "North Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03305341"
    },
    {
      "nct_id": "NCT03719300",
      "title": "Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-muscle Invasive Bladder Cancer (NMIBC)"
      ],
      "interventions": [
        {
          "name": "inodiftagene vixteplasmid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Anchiano Therapeutics Israel Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2019-03-20",
      "completion_date": "2019-12-18",
      "has_results": true,
      "last_update_posted_date": "2020-08-19",
      "last_synced_at": "2026-09-09T14:49:13.455Z",
      "location_count": 48,
      "location_summary": "Anchorage, Alaska • Gilbert, Arizona • Phoenix, Arizona + 40 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03719300"
    },
    {
      "nct_id": "NCT03345134",
      "title": "Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma",
        "Endoscopic Surgical Procedure",
        "Transitional Epithelial Cells"
      ],
      "interventions": [
        {
          "name": "MK-3475 and BCG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shaheen Alanee",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2017-11-30",
      "completion_date": "2021-01-01",
      "has_results": false,
      "last_update_posted_date": "2017-11-17",
      "last_synced_at": "2026-09-09T14:49:13.455Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03345134"
    },
    {
      "nct_id": "NCT05538663",
      "title": "Intravesical BCG vs GEMDOCE in NMIBC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-muscle-invasive Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Bacillus Calmette Guerin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ECOG-ACRIN Cancer Research Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 870,
      "start_date": "2023-02-07",
      "completion_date": "2030-10",
      "has_results": false,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-09-09T14:49:13.455Z",
      "location_count": 229,
      "location_summary": "Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 163 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05538663"
    },
    {
      "nct_id": "NCT05768347",
      "title": "Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Urothelial Carcinoma",
        "Non-Invasive Bladder Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2023-08-10",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-04",
      "last_synced_at": "2026-09-09T14:49:13.455Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05768347"
    }
  ]
}